The Future of Weight Loss: Exploring New Weight Loss Drugs 2025

What New Weight Loss Drugs Are On The Horizon?

As demand for effective weight loss treatments continues to soar, the landscape of weight management is evolving faster than ever. While established medications like Wegovy and Mounjaro have already transformed obesity care, 2025 marks a new era of innovation. Pharmaceutical companies are racing to develop new weight loss drugs, aiming to offer more powerful, more convenient, and natural solutions for patients struggling with obesity and weight-related health issues.

Among the most discussed are Orforglipron, CagriSema, Amycretin, Retatrutide, MariTide and natural supplements like Elcella. These new weight loss drugs aim to speed up weight loss, reduce side effects, or offer alternatives to injectable options, but are they effective?

These new weight loss drugs may sound appealing if you're searching for the best weight loss medications without injection or effective hunger suppressant pills online, but it’s essential to assess their clinical validation and long-term safety.

New Non-Injectable Weight Loss Drugs

If you're seeking a once-daily pill backed by promising trial results, Orforglipron has demonstrated up to 14.7% weight loss at 36 weeks in Phase 2 trials. However, it's not expected to be available until post-2026 and may come with mild gastrointestinal side effects. Amycretin, still in early trials, could offer even greater results by targeting both GLP-1 and amylin receptors, though more data is needed. For a natural, low-cost option available now, Elcella offers a 13% appetite reduction with no reported side effects (vendor claims), but weight loss outcomes remain unconfirmed.

New Injectable Weight Loss Drugs

Let’s compare these new injectable weight loss drugs:

• CagriSema - Injectable combo of semaglutide + cagrilintide
• Retatrutide - Injectable triple hormone receptor agonist (GLP-1, GIP, glucagon)
• MariTide - Injectable monthly treatment (GLP-1 + GIP agonist)

All harness hormone-based mechanisms for weight loss, but differ in how many pathways they target, how often they're taken, and how far along they are in clinical development:

Among injectables, CagriSema combines semaglutide and cagrilintide for enhanced appetite suppression, with trials showing up to 15.6% weight loss at 32 weeks. Retatrutide, a triple-action injection, goes even further, showing 24.2% average weight loss at 48 weeks in Phase 2 trials, though it's not expected until post-2027. MariTide offers a monthly injection alternative with around 20% weight loss over a year, potentially appealing to those seeking fewer doses and long-term effectiveness. If approved, this could be a more convenient alternative to weekly injections.

Medical Expert Insights

According to Chief Medical Officer, Dr. Charlotte Norton: “It is a really exciting time for the development of weight loss medication. With new medicines going through clinical trials with promising results, the options available for patients to find the right medication type and form will soon be broader. Key to selecting the right medication is to speak to an experienced clinician who can help you select the appropriate medicine based on your lifestyle, health and weight loss goals.”

What Options Are Currently Available & Clinically Proven For Weight Loss?

The future of weight medication is incredibly exciting, with more innovative options emerging each year. But while we look ahead to the next generation of new weight loss drugs, it’s important not to overlook the clinically proven treatments already available today:

• Wegovy (Semaglutide): A once-weekly GLP-1 injection.
• Mounjaro (Tirzepatide): A once-weekly injection targeting both GLP-1 and GIP receptors.
• Orlistat (Xenical): A daily weight loss pill that blocks fat absorption and supports calorie control.
• CAAS (Phentermine or Diethylpropion): A daily appetite suppressant tablet that reduces hunger.

Latest clinical trials report weight loss percentages of up to 22.5% for Mounjaro, up to 15% for Wegovy, around 5-10% for Orlistat, and approximately 5-10% for CAAS. Side effects are usually manageable and often improve over time, especially when treatment is closely monitored by a healthcare professional.

These options are available now and prescribed by our GMC-registered doctors, helping you begin your journey with safe, effective treatments backed by evidence.

More information about these medications can be found here: What is Wegovy, What is Mounjaro, What is Xenical, What is Phentermine, What is Diethylpriopion.

Take the Next Step

Ready to embark on your weight loss journey with confidence? Here at The Slimming Clinic, we offer a variety of treatments tailored to your health and weight loss goals. Book a free call back to discuss your options, or order online through our Online Pharmacy to start your journey today.